Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

36.67 +0.08 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Royalty Pharma Declares Third Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
From Royalty Pharma plc
Via GlobeNewswire
A Look Into Royalty Pharma Inc's Price Over Earnings
 
Via Benzinga
How Is The Market Feeling About Royalty Pharma?
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
2 Surging Stocks to Research Further and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
From Royalty Pharma plc
Via GlobeNewswire
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was... 
Via StockStory
2 Value Stocks to Target This Week and 1 to Turn Down
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
1 Stock Under $50 with Competitive Advantages and 2 to Question
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Royalty Pharma Completes the Acquisition of Its External Manager
From Royalty Pharma plc
Via GlobeNewswire
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share... 
Via StockStory
Royalty Pharma Reports First Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors 
Via Chartmill
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations.
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
3 Mid-Cap Stocks Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Topics Economy
Royalty Pharma Declares Second Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
From Royalty Pharma plc
Via GlobeNewswire
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,... 
Via StockStory
Topics Economy Government World Trade
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.